Cargando…

Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors

BACKGROUND: Long-acting somatostatin analogs (LA SSAs) are approved and recommended for the treatment of patients with advanced neuroendocrine tumors (NETs). Given the long duration of therapy and differences in administration routes, it is important to understand patients’ experiences with receivin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darden, Christina, Price, Mark, Ray, David, Goldstein, Grace, Goss, Diana, Bennett, Lee, Garbinsky, Diana, Thota, Ramya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423948/ https://www.ncbi.nlm.nih.gov/pubmed/34491454 http://dx.doi.org/10.1186/s41687-021-00355-5

Ejemplares similares

A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors
por: Seo, Caroline, et al.
Publicado: (2022)

PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly
por: O’Toole, Dermot, et al.
Publicado: (2022)

The Influence of Long-Acting Somatostatin Analogs on (68)Ga-DOTATATE Uptake in Patients With Neuroendocrine Tumors
por: Chahid, Youssef, et al.
Publicado: (2023)

Evaluation of long-acting somatostatin analog injection devices by nurses: a quantitative study
por: Adelman, Daphne T, et al.
Publicado: (2012)

Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors
por: Li, Daneng, et al.
Publicado: (2022)

Long-Acting Somatostatin Analogue Safety Monitoring Protocol for Outpatients With Neuroendocrine Tumors
por: Gabrielsen, Jordan, et al.
Publicado: (2019)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014)

Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs
por: Li, Su-Chen, et al.
Publicado: (2015)

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
por: Ortendahl, Jesse D, et al.
Publicado: (2017)

(225)Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic
por: Rubira, Léa, et al.
Publicado: (2023)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
por: Ehsanullah, Syed, et al.
Publicado: (2022)

Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
por: Bianchi, Antonio, et al.
Publicado: (2013)

Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs
por: Fernandes, Isabel, et al.
Publicado: (2012)

Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors
por: Fotouhi, Omid, et al.
Publicado: (2016)

Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs
por: Lenotti, Elisa, et al.
Publicado: (2021)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysis
por: Gurel, Michelle H., et al.
Publicado: (2017)

Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis
por: Wang, Rang, et al.
Publicado: (2023)

Case report: A particularly rare case of endogenous hyperinsulinemic hypoglycemia complicated with pregnancy treated with short-acting somatostatin analog injections
por: Barsi, Ádám, et al.
Publicado: (2022)

Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review
por: Boguszewski, Cesar L., et al.
Publicado: (2022)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Somatostatin Analogs in the Medical Management of Occult Bleeding of the Lower Digestive Tract
por: Martin-Grace, Julie, et al.
Publicado: (2015)

Role of Somatostatin Signalling in Neuroendocrine Tumours
por: Rogoza, Olesja, et al.
Publicado: (2022)

A Real-World Observational Study of the Use and Associated Costs of Treating Neuroendocrine Tumors With Somatostatin Analogs in Canada
por: Cheung, Winson Y., et al.
Publicado: (2022)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
por: Wolin, Edward M, et al.
Publicado: (2015)

Prescription patterns of long-acting somatostatin analogues
por: Machado-Alba, Jorge Enrique, et al.
Publicado: (2017)

Antiproliferative effects of somatostatin analogs in endocrine tumours
por: Zatelli, Maria Chiara
Publicado: (2009)

A review of the use of somatostatin analogs in oncology
por: Keskin, Ozge, et al.
Publicado: (2013)

Metastatic Insulinoma Managed with Radiolabeled Somatostatin Analog
por: Costa, Ricardo, et al.
Publicado: (2013)

Somatostatin analogs: is one better than other?
por: Rossana, Berardi, et al.
Publicado: (2017)

The Coordination Abilities of New Cyclic Analogs of Somatostatin
por: Marciniak, Aleksandra, et al.
Publicado: (2016)

Somatostatin Analogs in Clinical Practice: A Review
por: Gomes-Porras, Mariana, et al.
Publicado: (2020)

PMON57 Impact of Injection Modalities on Real-World Injection Experience in Patients with Acromegaly or Neuroendocrine Tumors (NETs) Treated With Somatostatin Analog (SSA) Therapy: Data from the PRESTO 2 Survey
por: Ribeiro-Oliveira, Antonio, et al.
Publicado: (2022)

Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells
por: Rossi, Valentina, et al.
Publicado: (2019)

Impact of Cold Somatostatin Analog Administration on Somatostatin Receptor Imaging: A Systematic Review
por: Morland, David, et al.
Publicado: (2023)

Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis
por: Merola, Elettra, et al.
Publicado: (2017)

A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
por: Hasic Telalovic, Jasminka, et al.
Publicado: (2021)

THU511 Somatostatin Analogs Or Active Surveillance In Sporadic And MEN1 Associated Non-functioning Pancreatic Neuroendocrine Tumors
por: Raia, Salvatore, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c63qro3snd1v62g39cqbbdu9bv